Clinical trial · Observational
Cryoablation for Advanced Bone and Soft Tissue Tumors
Safety and Efficacy of Cryoablation in the Treatment of Advanced Bone and Soft Tissue Tumors: a Single-center Retrospective Study
NCT05615545CI-TRIAL-00073801unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center, open, retrospective clinical study of patients with metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of selected tumor lesions. All eligible patients were enrolled. Basic data and treatment methods of these patients were collected, and efficacy and safety were evaluated.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cryoablation | — | UNRESOLVED | — |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cryoablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cryoablation
- description
- Cryoablation of selected tumor lesions
- interventionNames
- Procedure: Cryoablation
Primary outcomes (2)
- measure
- Survival rates
- timeFrame
- 12 months after surgery
- description
- 1-year survival rate
- measure
- There was no local recurrence survival rate
- timeFrame
- 12 months after surgery
- description
- The 1-year survival rate without local recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: No age restriction, male or female. The pathological diagnosis was a subtype of bone and soft tissue sarcoma. The clinical stage was determined to be metastatic or locally unresectable bone and soft tissue sarcoma. At least one cryoablation of tumor lesions was performed in our hospital. Target lesions can be evaluated according to the efficacy evaluation criteria for solid tumors (RECIST; Version 1.1) Measure diameter changes. Follow-up data were complete. Exclusion Criteria: Not applicable.
References
Publications (0)
Data not yet available
No reference posted for this study.